Yoon-Jeong Choi

Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial.

Byoung-Gie Kim, Y. Sung, S. Hur, 2020, The Lancet. Oncology.

Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment.

Albert Lai, Whitney B Pope, Stacey Green, 2018, International journal of radiation oncology, biology, physics.

Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults

Y. Sung, E. Shin, M. Song, 2022, The Lancet Microbe.

Efficacy and safety results of GX-188E, a therapeutic DNA vaccine, combined with pembrolizumab administration in patients with HPV 16- and/or 18- positive advanced cervical cancer: Phase II interim analysis results (KEYNOTE-567).

Byoung-Gie Kim, Y. Sung, S. Hur, 2021 .

GX-188E DNA vaccine plus pembrolizumab in HPV 16- and/or 18-positive recurrent or advance cervical cancer: a phase 2 trial

Sung Hoon Kim, J. Woo, Yoon-Jeong Choi, 2024, eClinicalMedicine.